Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Naoto Tachikawa"'
Autor:
Motoyasu Kusano, Yoshikazu Kinoshita, Ken Haruma, Katsuhiko Iwakiri, Mitsuhiro Fujishiro, Naoto Tachikawa
Publikováno v:
Current Therapeutic Research, Clinical and Experimental
Background The metabolism of many proton pump inhibitors is influenced by CYP2C19 genotype, which is a limitation of their use. Objectives To determine the efficacy and safety profile of Z-215 (azeloprazole sodium) as initial treatment for reflux eso
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ffc6f15a4d40e319cac2fe45725c124
https://doi.org/10.1016/j.curtheres.2018.03.004
https://doi.org/10.1016/j.curtheres.2018.03.004
Autor:
Naoto Tachikawa, Kazuhiko Odaka, Masakazu Nakano, Masakazu Ishimura, Yumi Kanegae, Izumu Saito, Joe Chiba, Saki Kondo
A recombinant adenovirus (rAd) expressing Cre recombinase derived from bacteriophage P1 has already been extensively used for the conditional gene activation and inactivation strategies in mammalian systems. In this study, we generated AxCAFLP, a rAd
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa5d3b6425e21e154160722338068650
https://europepmc.org/articles/PMC31301/
https://europepmc.org/articles/PMC31301/
Publikováno v:
The Proceedings of the Machine Design and Tribology Division meeting in JSME. :175-176
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ecf6152964bf506b4a112f140958889e
https://doi.org/10.1299/jsmemdt.2008.8.175
https://doi.org/10.1299/jsmemdt.2008.8.175
Autor:
Naoto Tachikawa, Miho Terashima, Izumu Saito, Saki Kondo, Hiromi Sato, Aya Okuda, Yumi Kanegae
Publikováno v:
Nucleic Acids Research. 31:76e-76
The site-specific recombinase Cre has often been used for on/off regulation of expression of transgenes introduced into the mammalian chromosome. However, this method is only applicable to the regulation of a single gene and cannot be used to simulta
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::badcce17e5a2ee33d9aa08dd6a16add0
https://doi.org/10.1093/nar/gng076
https://doi.org/10.1093/nar/gng076
Publikováno v:
Drugs in R&D
Introduction The effect of mesalazine in treating active Crohn’s disease (CD) remains controversial, possibly due to the various formulae of mesalazine used to treat inflammation located in different regions of the digestive tract. Methods This exp
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e2ab451b2e08bb92a65d5e432453d1f